Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SciBase
Stockholm, Swedenscibase.com ↗
- Ownership
- Public · SCIB
- Employees
- ~40
- Development stage
- Other
01
Overview
SciBase’s Nevisense is the only FDA-approved and CE Marked non-invasive device for melanoma detection, with over 300,000 patients tested globally. Clinical studies show improved diagnostic accuracy and more efficient biopsy management decisions compared to standard dermoscopy. The technology is supported by over 60 peer-reviewed publications.
- Therapeutic areas
- DermatologyOncology
- Modalities
- DeviceArtificial intelligence-based diagnostic platform (augmented intelligence)Electrical Impedance Spectroscopy (EIS)
- Industry
- Physiological Monitoring
02
Financials
- Market cap
- $95.5B
- Total revenue
- $36.2B
Beyond the preview
Go deeper on SciBase.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SciBase.